Jonas Ludvigsson

Jonas Ludvigsson

Professor
Besöksadress: Nobels väg 12a, 17165 Solna
Postadress: C8 Medicinsk epidemiologi och biostatistik, C8 MEB Ludvigsson, 171 77 Stockholm
Del av:

Om mig

  • Jag är professor vid Institutionen för medicinsk epidemiologi och biostatistik vid KI och överläkare vid Barnkliniken på Örebro Universitetssjukhus.
    Vänligen gå till den engelska sidan för mer information.

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Inflammatorisk tarmsjukdom, inflammation och risk för hjärtsjukdom
    Hjärt-Lungfonden
    1 January 2025 - 31 December 2027
  • Autism in Preterm Birth
    NICHD
    1 September 2024 - 31 August 2029
  • Swedish Research Council
    1 January 2024 - 31 December 2026
    RESEARCH PROBLEMAbout 1-2% of the Swedish population suffer from celiac disease. My earlier research has mainly focused on severe complications of celiac disease (e.g. death and cancer). In this project I will use laboratory data and primary care data to study early comorbidity in celiac disease, especially kidney-liver disease and neuro-cognitive/psychiatric disorders, such as stress-related illness, depression and dementia. DATA AND METHODProject 1: Through Swedish pathology departments, we have identified some 50,000 individuals with celiac disease. We expect that approx. 12-13,000 of these live in the Stockholm area and can therefore be linked to the laboratory database “SCREAM”. For these patients, we will identify all kidney and liver blood samples to follow kidney and liver function longitudinally.Project 2: Via a primary care dataset (covering 20 of 21 Swedish regions), we will examine celiac disease and the risk of neuro-cognitive disorders. WORK PLANProject 1: Using the personal identity number, data on celiac disease are linked to laboratory data in the SCREAM study. Using linear regression, we will study the development of early kidney and liver disease using laboratory data.Project 2: Data have already been linked. We will use Cox regression to calculate hazard ratios for our outcomes. RELEVANCEAn increased understanding of early comorbidity in celiac disease can improve the care of patients. In the long term, our goal is to prevent comorbidity in celiac disease.
  • Swedish Research Council
    1 January 2023 - 31 December 2025
    The purpose of this project is to increase our understanding of the etiology of Parkinson’s disease (PD). The project aims to: 1) investigate whether inflammatory gastrointestinal conditions, conditions related to perturbed gut microbiota, and gastrointestinal surgery are associated with PD risk, 2) investigate whether healthy dietary patterns, for example mediterranean and anti-inflammatory patterns, and antibiotics are associated with PD risk, 3) using network Mendelian randomization, test whether the gut microbiota composition is associated with PD risk or age at onset. Over four years, we will use cutting-edge conventional, genetic, and molecular epidemiological designs that aid causal inference, including Mendelian randomization and within-family studies. Resources will combine samples from the entire Swedish population (using the patient register), the unique database ESPRESSO with histopathological reports from gastrointestinal biopsies, the SIMPLER cohort with large numbers of DNA and fecal samples, as well as very large PD case control datasets with genetic information that were assembled in international genetic consortia.This research shifts the focus from identifying risk and protection factors associated with PD to establishing those likely to cause the disease, a step that will further understanding of disease etiology and pathogenesis. This will potentially lead to novel therapies, preventive strategies, and more individualized treatment of PD patients.
  • Consensus Statements for the Use of Routinely Collected Health Data in Inflammatory Bowel Disease Research
    Canadian Institutes of Health Research
    1 June 2022 - 31 May 2023
  • Canadian Institutes of Health Research
    1 June 2022 - 31 May 2023
  • Swedish Research Council
    1 December 2021 - 30 November 2025
    Autism Spectrum Disorder (ASD) risk is primarily of genetic origins. One source through which environmental effects may be influential is preterm birth (PTB
    birth &lt
    37 weeks gestation) which constitutes 6% of all births in Sweden (10% world wide). PTB is primarily of environmental origin, due to disease in the pregnant woman or her fetus. The processes underlying PTB may initiate ASD. This hypothesis has not been previously studied. If true, the heritability of ASD may be much lower in PTB children suggesting that PTB defines a subset of the general population where environmental risk play the major role for ASD risk.The goal of our project is to examine the ASD-etiology in PTB children and test if the etiology is different compared to term-born
    identify risk factors for ASD in PTB children, and to estimate the public health consequences of these factors.We will create a cohort of all Swedish children born 1995-2014 using the national registers, replicate results in Finland and examine genetic markers in a Swedish genetic sample.Aims are: (1) Determine the epidemiology and risk factors for ASD in PTB children. (2) Test if the risk factors in aim 1 are due to confounding, and estimate their public health consequences. (3) Compare ASD susceptibility in PTB and term-born children using both family data and molecular genetic data. (4) Explore potentials for risk prediction in a clinical cohortThis will be the most systematic investigation ASD-etiology in PTB children to date.
  • Swedish Research Council
    1 January 2021 - 31 December 2023
  • Inflammatory bowel disease and cancer risk - a moving target in an era of new immunomodulatory therapies
    Swedish Research Council
    1 January 2021 - 31 December 2024
  • Swedish Cancer Society
    1 January 2021
    Every year, one in three Swedes seeks care for gastrointestinal problems. A significant number have cancer, others have gastrointestinal diseases where there may be an increased risk of cancer. In our study, we will study: (1) gastrointestinal/liver disease and risk of cancer, (2) risk factors for gastrointestinal cancer, and (3) the prognosis of such cancer. Unlike the majority of previous international studies, by linking data from tissue samples from intestine/liver to Sweden's national health register, we will be able to study the entire population. It makes it possible to calculate precise cancer risks for average patients. We have established a brand new register of more than 2 million Swedes (Espresso), and will study the RISK OF CANCER in irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) such as e.g. Crohn's disease and ulcerative colitis, but also in liver diseases, the esophageal disease eosinophilic esophagitis
    RISK FACTORS FOR GASTROINTESTINAL CANCER such as colon cancer, and whether mucosal healing and medication can protect against IBD and liver cancer
    and finally PROGNOSIS in two less common forms of cancer (cholangiocarcinoma and small bowel cancer). Our goal is to be able to tailor individual patients' follow-up for gastrointestinal disease as well as their drug treatment to influence cancer development and mortality in gastrointestinal cancer. Our hope is that our project will lead to savings and make care more efficient. Furthermore, we want to conduct research that is relevant to the patient. Jonas Eriksson from the patient association Magtarmförbundet has participated in the planning of the studies (http://www.magotarm.se).
  • Swedish Research Council
    1 January 2020 - 31 December 2023
  • Risk of Cancer in Inflammatory Bowel Disease (IBD)
    Swedish Cancer Society
    1 January 2017
    More than 60,000 people in Sweden suffer from Crohn's disease or ulcerative colitis. Together, these diseases are referred to as "Inflammatory Bowel Disease" (IBD). Several previous studies have shown an increased risk of colon cancer in colon cancer, but the differences in results have been great, ranging from multiply increased risks to very small risk increases for cancer.   The incidence of IBD is increasing among children, but it is unclear whether IBD among children leads to an increased risk of cancer. Several IBD drugs appear to have a protective effect against colon cancer, but it is unclear whether the protective effect is due to mucosal healing and decreased inflammation. We will link diagnostic data for IBD from the National Patient Register with data from the Cancer Registry to calculate the risk of colon cancer (and for children also for lymphoma) at IBD. The new thing about our research is that we currently collect data from biopsy reports on IBD from Sweden's all 28 pathology departments. These biopsy reports contain unique information that will enable us to better calculate the risk of cancer, but also to study whether the medications given against IBD themselves protect against cancer development, and whether it is due to decreased inflammation of the intestinal mucosa. Many people with IBD are very concerned about the risk of cancer (especially colon cancer), the same applies to parents of children with IBD. With our study design we will be better able to answer whether IBD is a risk factor for cancer (for adults and children), and whether certain medications currently used against IBD not only relieve the IBD disease but also reduce the risk of cancer in the patients.   As part of the research, we also investigate how good / bad IBD is registered in the Patient Register. This will facilitate later cancer research within IBD.
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2017 - 31 December 2019
  • Swedish Research Council
    1 January 2017 - 31 December 2020
  • Risk of Cancer in Inflammatory Bowel Disease (IBD)
    Swedish Cancer Society
    1 January 2016
    More than 60,000 people in Sweden suffer from Crohn's disease or ulcerative colitis. Together, these diseases are referred to as "Inflammatory Bowel Disease" (IBD). Several previous studies have shown an increased risk of colon cancer in colon cancer, but the differences in results have been great, ranging from multiply increased risks to very small risk increases for cancer.   The incidence of IBD is increasing among children, but it is unclear whether IBD among children leads to an increased risk of cancer. Several IBD drugs appear to have a protective effect against colon cancer, but it is unclear whether the protective effect is due to mucosal healing and decreased inflammation. We will link diagnostic data for IBD from the National Patient Register with data from the Cancer Registry to calculate the risk of colon cancer (and for children also for lymphoma) at IBD. The new thing about our research is that we currently collect data from biopsy reports on IBD from Sweden's all 28 pathology departments. These biopsy reports contain unique information that will enable us to better calculate the risk of cancer, but also to study whether the medications given against IBD themselves protect against cancer development, and whether it is due to decreased inflammation of the intestinal mucosa. Many people with IBD are very concerned about the risk of cancer (especially colon cancer), the same applies to parents of children with IBD. With our study design we will be better able to answer whether IBD is a risk factor for cancer (for adults and children), and whether certain medications currently used against IBD not only relieve the IBD disease but also reduce the risk of cancer in the patients.   As part of the research, we also investigate how good / bad IBD is registered in the Patient Register. This will facilitate later cancer research within IBD.
  • Risk of Cancer in Inflammatory Bowel Disease (IBD)
    Swedish Cancer Society
    1 January 2015
    More than 60,000 people in Sweden suffer from Crohn's disease or ulcerative colitis. Together, these diseases are referred to as "Inflammatory Bowel Disease" (IBD). Several previous studies have shown an increased risk of colon cancer in colon cancer, but the differences in results have been great, ranging from multiply increased risks to very small risk increases for cancer.   The incidence of IBD is increasing among children, but it is unclear whether IBD among children leads to an increased risk of cancer. Several IBD drugs appear to have a protective effect against colon cancer, but it is unclear whether the protective effect is due to mucosal healing and decreased inflammation. We will link diagnostic data for IBD from the National Patient Register with data from the Cancer Registry to calculate the risk of colon cancer (and for children also for lymphoma) at IBD. The new thing about our research is that we currently collect data from biopsy reports on IBD from Sweden's all 28 pathology departments. These biopsy reports contain unique information that will enable us to better calculate the risk of cancer, but also to study whether the medications given against IBD themselves protect against cancer development, and whether it is due to decreased inflammation of the intestinal mucosa. Many people with IBD are very concerned about the risk of cancer (especially colon cancer), the same applies to parents of children with IBD. With our study design we will be better able to answer whether IBD is a risk factor for cancer (for adults and children), and whether certain medications currently used against IBD not only relieve the IBD disease but also reduce the risk of cancer in the patients.   As part of the research, we also investigate how good / bad IBD is registered in the Patient Register. This will facilitate later cancer research within IBD.
  • Council for International Exchange of Scholars
    1 January 2012 - 30 April 2012
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2011 - 31 December 2013
  • Swedish Research Council
    1 January 2010 - 31 December 2010
  • Swedish Research Council
    1 January 2010 - 31 December 2013
  • Visa fler

Anställningar

  • Professor, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2013-

Examina och utbildning

  • Docent, 2005

Nyheter från KI

Kalenderhändelser från KI